Stock Code: 600380 Stock Short Name: 健康元
Joincare Pharmaceutical Group Industry Co., Ltd.
2024 First Quarterly Report
The Board of Directors and all Directors of the Company hereby warrant that there are no falserepresentations, misleading statements or material omissions contained in this announcement andaccept legal responsibility for the truthfulness, accuracy and completeness of the contents hereof.
IMPORTANT NOTICE:
? The Board of Directors, the Board of Supervisors and Directors, Supervisors and senior managementof the Company hereby warrant the truthfulness, accuracy and completeness of the contents of thisquarterly report, and that there are no false representations, misleading statements or materialomissions contained herein, and severally and jointly accept legal responsibility.
? The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-charge of the accounting department (the head of the accounting department) hereby warrant thetruthfulness, accuracy and completeness of the financial information contained in this quarterly report.
? Whether the first quarterly financial statements have been audited.
□Yes √No
I. MAJOR FINANCIAL DATA(I) Major Accounting Data and Financial Indicators
Unit: Yuan Currency: RMB
| Item | The Reporting Period (From January to March) | YoY change (%) |
| Revenues | 4,339,814,452.16 | -4.81 |
| Net profit attributable to shareholders of the listed company | 439,798,106.55 | -4.96 |
| Net profit attributable to shareholders of the listed company after deduction of extraordinary gains and losses | 427,753,549.19 | -4.26 |
| Net cash flow from operating activities | 972,276,972.65 | 291.91 |
| Basic earnings per share (RMB/share) | 0.2357 | -1.96 |
| Diluted earnings per share (RMB/share) | 0.2355 | -1.82 |
| Weighted average return on net assets (%) | 3.15 | Decreased by 0.34 percentage points |
| As at the end of the Reporting Period | As at the end of the previous year | Change as at the end of the Reporting Period as compared to the end of the previous year(%) | |
| Total assets | 36,462,147,240.89 | 36,358,126,258.82 | 0.29 |
| Owner's equity attributable to shareholders of the listed company | 14,234,869,509.55 | 13,755,901,924.06 | 3.48 |
Notes: From January to March 2024, the Company Chemical pharmaceuticals realized revenues of RMB2,141million, representing a YoY decrease of 4.86%, among which, RMB807 million were from gonadotropichormones, representing a YoY increase of 39.89%; RMB589 million were from gastroenterology products,representing a YoY decrease of 25.68%; RMB417 million were from respiratory formulation products,representing a YoY decrease of 18.17%; RMB135 million were from psychiatry products, representing a YoYincrease of 10.11%; and RMB115 million were from anti-infection products, representing a YoY decrease of
42.20%. APIs and intermediates products realized revenues of RMB1,399 million, representing a YoY decreaseof 3.70%. Traditional Chinese Medicine products realized revenues of RMB406 million, representing a YoYdecrease of 28.38%. Diagnostic reagents and equipment products realized revenues of RMB236 million from,representing a YoY increase of 60.26%. Health care products realized revenues of RMB78 million, representinga YoY increase of 96.50%. Biological products realized revenues of RMB44 million, representing a YoYdecrease of 29.86%.
(II) Items and Amounts of Extraordinary Gains and Losses
Unit: Yuan Currency: RMB
| Item | For the Reporting Period | Explanation |
| Gains and losses on disposal of non-current assets (including the reversal of asset impairment provisions already recognized) | 306,572.18 | Proceeds from disposal of fixed assets |
| Government grants recognized in profit and loss for current period (except for government grants closely associated with corporate businesses, entitled at fixed amount or fixed level according to the national polices and standards) | 23,948,950.14 | Government grants through the profits and losses for the Period |
| Gains and losses on fair value changes incurred from financial assets held for trading, derivative financial assets, financial liabilities held for trading and derivative financial liabilities, and investment income on disposal of financial assets held for trading, derivative financial assets, financial liabilities held for trading, derivative financial liabilities and other debt investments, except for effective hedging activities related to the ordinary operating business of the Company | 3,385,577.72 | Gains or losses arising from changes in fair value of financial assets/liabilities held for trading, and investment gains from holding and disposal of financial assets/liabilities held for trading |
| Other non-operating income and expenses apart from the above items | -3,998,396.15 | Other non-operating income and expenses excluding the above items |
| Less: Effect of income tax | 1,860,588.22 | Effect of the above items on income tax |
| Effect of minority equity (after tax) | 9,737,558.31 | The portion of the above items to which minority shareholders are entitled |
| Total | 12,044,557.36 |
Explanations for significant amount of extraordinary gain or loss items identified by the Company but notlisted in the “Explanatory Announcement No.1 for Public Company Information Disclosures –Extraordinary Gains or Losses”, and recurring gain or loss items identified by the Company which arelisted as extraordinary gain or loss items in the “Explanatory Announcement No.1 for Public CompanyInformation Disclosures –Extraordinary Gains or Losses”.
□Applicable √N/A
(III) Changes in Major Accounting Data and Financial Indicators and Reasons Thereof
√Applicable □N/A
| Item | Change (%) | Explanation |
| Net cash flow from operating activities | 291.91 | Mainly due to the decrease in procurement and expenses. |
(IV) Material Changes in Other Items in Financial Statements and Financial Indicators and ReasonsThereof
Unit: Yuan Currency: RMB
| Balance Sheet | 31 March 2024 | 31 December 2023 | Change in proportion （%） | Main Reason |
| Other receivables | 62,309,748.02 | 46,010,624.61 | 35.42 | Mainly due to the increase in the receivables of export tax refund for the Period. |
| Non-current assets due within one year | 273,390,415.52 | 406,376,425.44 | -32.72 | Mainly due to the withdrawal of fixed-term deposits due within one year. |
| Other current assets | 194,698,002.02 | 77,402,185.01 | 151.54 | Mainly due to the new short-term cash management business. |
| Other non-current assets | 1,446,707,336.74 | 957,224,255.77 | 51.14 | Mainly due to the new medium to long-term cash management business. |
| Short-term loans | 1,360,009,625.00 | 2,076,159,347.22 | -34.49 | Mainly due to the repayment maturing loans during the Period. |
| Financial liabilities held for trading | 4,654,285.13 | 86,817.12 | 5,261.02 | Mainly due to changes in forward foreign exchange contracts. |
| Contract liabilities | 89,641,348.22 | 159,082,637.65 | -43.65 | Mainly because part of the contract payments received in advance in the Period which met the conditions for revenue recognition were transferred to revenues. |
| Employee benefits payable | 233,225,870.33 | 399,466,473.91 | -41.62 | Mainly due to the payment of year-end bonuses to employees during the Period. |
| Non-current liabilities due within one year | 1,397,628,656.81 | 718,564,144.31 | 94.50 | Mainly due to the transfer of long-term borrowings due within one year. |
| Other comprehensive income | -22,278,942.52 | -12,246,131.22 | N/A | Mainly due to the fair value changes of other equity instrument investments and the impact of foreign currency translation on financial statements. |
| Income Statement | January to March 2024 | January to March 2023 | Change in proportion （%） | Main Reason |
| Financial expenses | -73,644,643.56 | -15,861,425.43 | N/A | Mainly due to the increase in interest income from deposits for the Period as compared with the previous period. |
| Other income | 35,611,817.69 | 54,191,288.49 | -34.28 | Mainly due to the decrease in government grants for the Period as compared with the previous period. |
| Investment income | 20,421,061.35 | 39,625,949.95 | -48.47 | Mainly due to the receipt of dividend payments in the previous period. |
| Gains from changes in fair values | 1,161,062.53 | -27,478,190.74 | N/A | Mainly due to fluctuations in market value of the securities investment held. |
| Losses of credit impairment | -6,583,395.98 | -15,459,174.59 | N/A | Mainly due to aging changes of accounts receivables resulting in the corresponding decrease in expected credit loss during the Period. |
| Assets impairment loss | -4,077,243.26 | 1,837,691.27 | -321.87 | Mainly due to the increase in the impairment provision of inventories for the Period as compared with the previous period. |
| Non-operating income | 1,879,698.62 | 876,580.36 | 114.44 | Mainly due to an increase in income from disposal of scraps during the Period. |
| Non-operating expenses | 5,878,094.77 | 3,698,829.74 | 58.92 | Mainly due to an increase in write-off losses of assets during the Period. |
| Cash Flow Statement | January to March 2024 | January to March 2023 | Change in proportion （%） | Main Reason |
| Net cash flow from operating activities | 972,276,972.65 | 248,084,750.71 | 291.91 | Mainly due to the decrease in procurement and expenses. |
| Net cash flow from investing activities | -660,694,051.81 | -71,511,309.54 | N/A | Mainly due to an increase in investment payments for the Period. |
| Net cash flow from financing activities | -894,822,792.10 | -118,644,351.81 | N/A | Mainly due to the decrease in new borrowings and the increase in repayment of borrowings for the Period. |
| Effect of exchange rate fluctuations on cash and cash equivalents | 4,074,463.63 | -47,773,910.21 | N/A | Mainly due to changes in foreign exchange rates resulting in a decrease in exchange loss from foreign exchange funds held. |
II. SHAREHOLDERS(I) Total Number of Holders of Ordinary Shares and Number of Holders of Preferred Shares with RestoredVoting Rights and Shareholdings of Top 10 Shareholders
Unit: shares
| Total number of holders of ordinary shares as of the end of the Reporting Period | 78,332 | Total number of holders of preferred shares with restored voting rights as of the end of the Reporting Period (if any) | 0 | ||||
| Shareholdings of the top 10 shareholders (excluding shares lent through refinancing business) | |||||||
| Name of shareholder | Nature of shareholder | Number of shares held | Percentage (%) | Number of shares held with selling restrictions | Pledge, mark or lock-up | ||
| Share status | Number | ||||||
| Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源投资有限公司) | Domestic non-state-owned legal person | 895,653,653 | 47.98 | 0 | Pledge | 75,679,725 | |
| Hong Kong Securities Clearing Company Limited | Unknown | 87,780,030 | 4.70 | 0 | Unknown | ||
| Might Seasons Limited | Foreign legal person | 35,929,699 | 1.92 | 0 | Unknown | ||
| Perseverance Asset Management L.L.P–Gaoyi Xiaofeng No. 2 Zhixin Fund | Unknown | 17,161,348 | 0.92 | 0 | Unknown | ||
| China Foreign Economy and Trade Trust Co., Ltd.–Foreign Trust–Gaoyi Xiaofeng Hongyuan Collection Fund Trust Plan | Unknown | 16,677,148 | 0.89 | 0 | Unknown | ||
| Huaxia Life Insurance Co., Ltd. -Proprietary | Unknown | 12,729,218 | 0.68 | 0 | Unknown | ||
| Abu Dhabi Investment Authority | Foreign legal person | 11,347,653 | 0.61 | 0 | Unknown | ||
| CPIC Fund -China Pacific Life Insurance Co., Ltd. -with-profit insurance-CPIC Fund ChinaPacific Life Equity Relative Income (Guaranteed Dividend) single assets management plan | Unknown | 10,731,762 | 0.57 | 0 | Unknown | ||
| Agricultural Bank of China Limited –CSI 500 Exchange Traded Index Securities Investment Fund | Unknown | 10,353,414 | 0.55 | 0 | Unknown | ||
| Joincare Pharmaceutical Group Industry Co., Ltd. —the Third Phase Ownership Scheme under Medium to Long-term Business Partner Share Ownership Scheme | Others | 9,370,400 | 0.50 | 0 | - | ||
| Shareholdings of the top 10 shareholders without selling restrictions | |||||||
| Name of shareholder | Number of tradable shares held without selling restrictions | Class and number of shares | |||||
| Class of shares | Number | ||||||
| Shenzhen Baiyeyuan Investment Co., Ltd. (深圳市百业源投资有限公司) | 895,653,653 | Ordinary shares denominated in Renminbi | 895,653,653 | ||||
| Hong Kong Securities Clearing Company Limited | 87,780,030 | Ordinary shares denominated in Renminbi | 87,780,030 | ||||
| Might Seasons Limited | 35,929,699 | Ordinary shares denominated in Renminbi | 35,929,699 | ||||
| Perseverance Asset Management L.L.P–Gaoyi Xiaofeng No. 2 Zhixin Fund | 17,161,348 | Ordinary shares denominated in Renminbi | 17,161,348 | ||||
| China Foreign Economy and Trade Trust Co., Ltd.–Foreign Trust–Gaoyi Xiaofeng Hongyuan Collection Fund Trust Plan | 16,677,148 | Ordinary shares denominated in Renminbi | 16,677,148 | ||||
| Huaxia Life Insurance Co., Ltd. -Proprietary | 12,729,218 | Ordinary shares denominated in Renminbi | 12,729,218 | ||||
| Abu Dhabi Investment Authority | 11,347,653 | Ordinary shares denominated in Renminbi | 11,347,653 | ||||
| CPIC Fund -China Pacific Life Insurance Co., Ltd. -with-profit insurance-CPIC Fund ChinaPacific Life Equity Relative Income (Guaranteed Dividend) single assets management plan | 10,731,762 | Ordinary shares denominated in Renminbi | 10,731,762 | ||||
| Agricultural Bank of China Limited –CSI 500 Exchange Traded Index Securities Investment Fund | 10,353,414 | Ordinary shares denominated in Renminbi | 10,353,414 | ||||
| Joincare Pharmaceutical Group Industry Co., Ltd. —the Third Phase Ownership Scheme under Medium to Long-term Business Partner Share Ownership Scheme | 9,370,400 | Ordinary shares denominated in Renminbi | 9,370,400 | ||||
| Description of connection or acting-in-concert relationship of the above shareholders | There was no connection or acting-in-concert relationship between Shenzhen Baiyeyuan Investment Co., Ltd., a controlling shareholder of the Company, and other shareholders; whether there is connection or acting-in-concert relationship among other shareholders is unknown. | ||||||
| Description of the participation of the top 10 shareholders and the top 10 shareholders without selling restrictions in margin financing and securities lending and refinancing business (if any) | The participation of the top 10 shareholders and the top 10 shareholders without selling restrictions in securities lending and refinancing business is detailed in the table below. |
Participation of shareholders holding over 5%, the top 10 shareholders, and the top 10 shareholderswithout selling restriction in securities lending transactions of refinancing business
√Applicable □N/A
Unit: shares
| Participation of shareholders holding over 5%, the top 10 shareholders, and the top 10 shareholders without selling restriction in securities lending transactions of refinancing business | ||||||||
| Name of shareholder (Full name) | Number of shares held in ordinary and credit accounts at the beginning of the Period | Number of shares lent through refinancing business and not yet returned at the beginning of the Period | Number of shares held in ordinary and credit accounts at the end of the Period | Number of shares lent through refinancing business and not yet returned at the end of the Period | ||||
| Total number | Proportion (%) | Total number | Proportion (%) | Total number | Proportion (%) | Total number | Proportion (%) | |
| Agricultural Bank of China Limited –CSI 500 Exchange Traded Index Securities Investment Fund | 5,055,774 | 0.27 | 1,509,200 | 0.08 | 10,353,414 | 0.55 | 801,600 | 0.04 |
Changes in the top 10 shareholders and the top 10 shareholders without selling restriction due to securitieslending/returning transactions of refinancing business compared to the previous period
√Applicable □N/A
Unit: shares
| Changes in the top 10 shareholders and the top 10 shareholders without selling restriction due to securities lending/returning transactions of refinancing business compared to the previous period | |||||
| Name of shareholder (Full name) | New / withdrawn shareholdings during the Period | Number of shares lent through refinancing business and not yet returned at the end of the Period | Number of shares held by shareholders in ordinary and credit accounts, and lent through refinancing business and not yet returned at the end of the Period | ||
| Total number | Proportion (%) | Total number | Proportion (%) | ||
| Agricultural Bank of China Limited –CSI 500 Exchange Traded Index Securities Investment Fund | New | 801,600 | 0.04 | 11,155,014 | 0.60 |
III. OTHER REMINDERSOther important information regarding the Company’s operations during the Reporting Period to whichinvestors should be reminded to pay attention.
□Applicable √N/A
IV. QUARTERLY FINANCIAL STATEMENTS(I) Audit Opinion
□Applicable √N/A
(II) Financial Statements
Consolidated Balance Sheet
31 March 2024Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | 31 March 2024 | 31 December 2023 |
| Current assets: | ||
| Cash and bank balances | 15,118,198,045.39 | 15,691,888,314.83 |
| Financial assets held for trading | 88,627,684.77 | 82,899,154.24 |
| Notes receivable | 2,132,604,341.62 | 1,941,200,568.00 |
| Accounts receivable | 2,641,495,146.49 | 2,692,941,866.24 |
| Receivables financing | ||
| Prepayments | 320,528,020.48 | 280,102,860.94 |
| Other receivables | 62,309,748.02 | 46,010,624.61 |
| Including: Interests receivable | ||
| Dividends receivable | ||
| Inventories | 2,611,899,764.18 | 2,655,808,391.09 |
| Contract assets | ||
| Assets Held-for-sale | ||
| Non-current assets due within one year | 273,390,415.52 | 406,376,425.44 |
| Other current assets | 194,698,002.02 | 77,402,185.01 |
| Total current assets | 23,443,751,168.49 | 23,874,630,390.40 |
| Non-current assets: | ||
| Debt investment | ||
| Other debt investment | ||
| Long-term receivables | ||
| Long-term equity investment | 1,441,192,028.13 | 1,411,036,353.95 |
| Other equity instrument investments | 1,125,075,861.47 | 1,155,283,408.36 |
| Other non-current financial assets | ||
| Investment properties | 16,747,992.14 | 16,958,213.00 |
| Fixed assets | 5,599,470,118.92 | 5,664,352,555.97 |
| Construction in progress | 604,817,101.51 | 531,059,118.06 |
| Productive biological assets | ||
| Oil and gas assets | ||
| Right-of-use assets | 31,763,462.07 | 36,233,067.49 |
| Intangible assets | 680,629,773.47 | 683,337,333.73 |
| Development expenditures | 512,933,455.84 | 483,494,487.17 |
| Goodwill | 636,339,503.82 | 636,339,503.82 |
| Long-term deferred expenses | 338,816,538.46 | 328,642,740.95 |
| Deferred income tax assets | 583,902,899.83 | 579,534,830.15 |
| Other non-current assets | 1,446,707,336.74 | 957,224,255.77 |
| Total non-current assets | 13,018,396,072.40 | 12,483,495,868.42 |
| Total assets | 36,462,147,240.89 | 36,358,126,258.82 |
| Current liabilities: | ||
| Short-term loans | 1,360,009,625.00 | 2,076,159,347.22 |
| Financial liabilities held for trading | 4,654,285.13 | 86,817.12 |
| Notes payable | 1,709,979,271.07 | 1,469,148,287.38 |
| Accounts payable | 839,740,488.88 | 894,286,243.28 |
| Receipts in advance | ||
| Contract liabilities | 89,641,348.22 | 159,082,637.65 |
| Employee benefits payable | 233,225,870.33 | 399,466,473.91 |
| Taxes payable | 290,242,285.97 | 410,202,854.09 |
| Other payables | 3,894,003,172.09 | 3,682,604,038.73 |
| Including: Interests payable | ||
| Dividends payable | 11,458,767.63 | 12,478,280.13 |
| Liabilities held-for-sale | ||
| Non-current liabilities due within one year | 1,397,628,656.81 | 718,564,144.31 |
| Other current liabilities | 46,181,338.66 | 51,087,001.83 |
| Total current liabilities | 9,865,306,342.16 | 9,860,687,845.52 |
| Non-current liabilities: | ||
| Long-term loans | 2,343,143,096.02 | 3,122,273,278.99 |
| Bonds payable | ||
| Lease liabilities | 11,556,383.03 | 15,422,948.41 |
| Long-term payables | ||
| Long-term payroll payable | ||
| Estimated liabilities | ||
| Deferred income | 362,705,046.07 | 370,179,550.82 |
| Deferred income tax liabilities | 252,778,619.58 | 260,032,144.44 |
| Other non-current liabilities | 90,000,000.00 | 90,000,000.00 |
| Total non-current liabilities | 3,060,183,144.70 | 3,857,907,922.66 |
| Total liabilities | 12,925,489,486.86 | 13,718,595,768.18 |
| Owner's equity (or shareholder's equity): | ||
| Paid-in Capital (or Share capital) | 1,866,634,764.00 | 1,865,523,807.00 |
| Other equity instruments | ||
| Including: Preferred shares | ||
| Perpetual debts | ||
| Capital reserve | 1,652,811,420.95 | 1,601,720,087.71 |
| Less: Treasury shares | ||
| Other comprehensive income | -22,278,942.52 | -12,246,131.22 |
| Special reserve | ||
| Surplus reserve | 859,046,203.77 | 859,046,203.77 |
| Undistributed profits | 9,878,656,063.35 | 9,441,857,956.80 |
| Total owner's equity (or shareholder's equity) attributable to the parent company | 14,234,869,509.55 | 13,755,901,924.06 |
| Minority shareholder's equity | 9,301,788,244.48 | 8,883,628,566.58 |
| Total owner's equity (or shareholder's equity) | 23,536,657,754.03 | 22,639,530,490.64 |
| Total liabilities and owner's equity (or shareholder's equity) | 36,462,147,240.89 | 36,358,126,258.82 |
Person-in-charge of theCompany: Zhu Baoguo
Person-in-charge of theCompany's accounting work:
Qiu Qingfeng
Person-in-charge of theaccounting department:
Guo Chenlu
Consolidated Income StatementFrom January to March, 2024Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | First quarter (January to March) for 2024 | First quarter (January to March) for 2023 |
| I. Total revenues | 4,339,814,452.16 | 4,559,049,786.82 |
| Including: Operating revenues | 4,339,814,452.16 | 4,559,049,786.82 |
| II. Total operating costs | 3,296,136,273.86 | 3,563,214,097.57 |
| Including: Operating costs | 1,588,615,523.54 | 1,713,465,807.02 |
| Operating tax and surcharges | 46,715,949.27 | 54,610,788.80 |
| Selling expenses | 1,097,660,861.66 | 1,220,569,090.59 |
| Administrative expenses | 259,688,090.97 | 209,257,340.10 |
| R&D expenses | 377,100,491.98 | 381,172,496.49 |
| Financial expenses | -73,644,643.56 | -15,861,425.43 |
| Including: Interest expenses | 33,732,578.57 | 33,036,361.57 |
| Interest income | 102,748,969.84 | 68,217,553.45 |
| Add: Other income | 35,611,817.69 | 54,191,288.49 |
| Investment Income (“-” for loss) | 20,421,061.35 | 39,625,949.95 |
| Including: Income from investments in associates and joint ventures | 18,196,546.16 | 11,470,389.65 |
| Gains from derecognition of financial assets at amortized cost | ||
| Gains from net exposure hedges (“-” for loss) | ||
| Gains from changes in fair values (“-” for loss) | 1,161,062.53 | -27,478,190.74 |
| Losses of credit impairment (“-” for loss) | -6,583,395.98 | -15,459,174.59 |
| Assets impairment loss (“-” for loss) | -4,077,243.26 | 1,837,691.27 |
| Gains from disposal of assets (“-” for loss) | 306,572.18 | |
| III. Operating profit (“-” for loss) | 1,090,518,052.81 | 1,048,553,253.63 |
| Add: Non-operating income | 1,879,698.62 | 876,580.36 |
| Less: Non-operating expenses | 5,878,094.77 | 3,698,829.74 |
| IV. Total profit (“-” for loss) | 1,086,519,656.66 | 1,045,731,004.25 |
| Less: Income tax expenses | 161,422,518.85 | 167,212,968.94 |
| V. Net profit (“-” for loss) | 925,097,137.81 | 878,518,035.31 |
| (I) Classified by business continuity | ||
| 1. Net profit from ongoing operation (“-” for loss) | 925,097,137.81 | 878,518,035.31 |
| 2. Net profit from discontinuing operation (“-” for loss) | ||
| (II) Classified by ownership | ||
| 1.Net profit attributable to shareholders of the parent company (“-” for loss) | 439,798,106.55 | 462,746,183.03 |
| 2.Profit and loss of minority shareholders (“-” for loss) | 485,299,031.26 | 415,771,852.27 |
| VI. Other comprehensive income, net of tax | -22,546,561.73 | -83,671,573.75 |
| (I) Other comprehensive income attributable to shareholders of the parent, net of tax | -10,032,811.30 | -47,285,378.94 |
| 1. Other comprehensive income that cannot be reclassified into profit or loss | -10,449,421.02 | -20,803,179.78 |
| (1) Changes from remeasurement of defined benefit plans | ||
| (2) Other comprehensive income that cannot be reclassified into profit or loss under the equity method | ||
| (3) Changes in fair value of investments in other equity instruments | -10,449,421.02 | -20,803,179.78 |
| (4) Changes in fair value of the enterprise's own credit risks | ||
| 2. Other comprehensive income that will be reclassified into profit or loss | 416,609.72 | -26,482,199.17 |
| (1) Other comprehensive income that can be reclassified into profit or loss under the equity method | ||
| (2) Changes in fair value of other debt investments | ||
| (3) Amount of financial assets reclassified into other comprehensive income | ||
| (4) Provision for credit impairment of other debt investments | ||
| (5) Reserve for cash flow hedges | ||
| (6) Exchange translation differences on financial statements denominated in foreign currencies | 416,609.72 | -26,482,199.17 |
| (7) Others | ||
| (II) Other comprehensive income attributable to minority shareholders, net of tax | -12,513,750.43 | -36,386,194.81 |
| VII. Total comprehensive income | 902,550,576.08 | 794,846,461.55 |
| (I) Total comprehensive income attributable to owners of the parent company | 429,765,295.25 | 415,460,804.09 |
| (II) Total comprehensive income attributable to minority shareholders | 472,785,280.83 | 379,385,657.46 |
| VIII. Earnings per share: | ||
| (I) Basic earnings per share (RMB/share) | 0.2357 | 0.2404 |
| (II) Diluted earnings per share (RMB/share) | 0.2355 | 0.2398 |
Person-in-charge of theCompany: Zhu Baoguo
Person-in-charge of theCompany's accounting work:
Qiu Qingfeng
Person-in-charge of theaccounting department:
Guo Chenlu
Consolidated Cash Flow StatementFrom January to March, 2024Prepared by: Joincare Pharmaceutical Group Industry Co., Ltd.
Unit: Yuan Currency: RMB Audit status: Unaudited
| Item | First quarter (January to March) for 2024 | First quarter (January to March) for 2023 |
| I. Cash flow from operating activities: | ||
| Cash received from sales of goods and rendering of services | 4,476,359,723.04 | 4,361,096,155.32 |
| Tax refunds received | 22,324,907.54 | 40,439,680.21 |
| Other cash received related to operating activities | 138,196,959.28 | 202,829,024.01 |
| Subtotal of cash inflow from operating activities | 4,636,881,589.86 | 4,604,364,859.54 |
| Cash paid for goods and services | 1,141,145,195.81 | 1,563,463,357.75 |
| Cash paid to and on behalf of employees | 893,901,217.41 | 820,337,183.05 |
| Payments of all types of taxes | 613,555,586.00 | 541,191,286.96 |
| Other cash paid related to operating activities | 1,016,002,617.99 | 1,431,288,281.07 |
| Subtotal of cash outflow in operating activities | 3,664,604,617.21 | 4,356,280,108.83 |
| Net cash flow from operating activities | 972,276,972.65 | 248,084,750.71 |
| II. Cash flow from investing activities: | ||
| Cash received from disposal of investment | 70,031,257.75 | |
| Cash received from investment income | 5,834,420.64 | 26,244,584.66 |
| Net cash received from disposal of fixed assets, intangible assets and other long-term assets | 285,580.00 | 88,664.00 |
| Net cash received from disposal of subsidiaries and other business units | ||
| Other cash received related to investing activities | 199,305,000.00 | 297,605,105.05 |
| Subtotal of cash inflow from investing activities | 205,425,000.64 | 393,969,611.46 |
| Cash paid for purchase and construction of fixed assets, intangible assets and other long-term assets | 248,170,722.58 | 244,675,030.69 |
| Cash paid to acquire investment | 307,546,469.39 | 6,183,753.84 |
| Net cash paid for acquisition of subsidiaries and other business units | 12,461,951.59 | |
| Other cash paid related to investing activities | 310,401,860.48 | 202,160,184.88 |
| Subtotal of cash outflow in investing activities | 866,119,052.45 | 465,480,921.00 |
| Net cash flow from investing activities | -660,694,051.81 | -71,511,309.54 |
| III. Cash flow from financing activities: | ||
| Cash received from capital contribution | 95,333,159.21 | |
| Including: Cash received from investment by minority interests of subsidiaries | 82,448,734.79 | |
| Cash received from borrowings | 642,754,935.91 | 1,249,525,870.74 |
| Other cash received related to financing activities | 86,192.20 | |
| Subtotal of cash inflow from financing activities | 738,174,287.32 | 1,249,525,870.74 |
| Cash repayments of amounts borrowed | 1,459,815,571.50 | 715,074,985.04 |
| Cash payments for interest expenses and distribution of dividends or profits | 39,274,885.57 | 41,156,153.68 |
| Including: Dividends and profit paid to minority interests of subsidiaries | 5,819,512.50 | 359,270.18 |
| Other cash payments related to financing activities | 133,906,622.35 | 611,939,083.83 |
| Subtotal of cash outflow in financing activities | 1,632,997,079.42 | 1,368,170,222.55 |
| Net cash flow from financing activities | -894,822,792.10 | -118,644,351.81 |
| IV. Effect of exchange rate fluctuations on cash and cash equivalents | 4,074,463.63 | -47,773,910.21 |
| V. Net increase in cash and cash equivalents | -579,165,407.63 | 10,155,179.14 |
| Add: Opening balance of cash and cash equivalents | 15,340,869,372.73 | 14,178,465,686.40 |
| VI. Closing balance of cash and cash equivalents | 14,761,703,965.10 | 14,188,620,865.54 |
Person-in-charge of theCompany: Zhu Baoguo
Person-in-charge of theCompany's accounting work:
Qiu Qingfeng
Person-in-charge of theaccounting department:
Guo Chenlu
(III) Implementation of new accounting standards or interpretations of standards, for the first time from2024 involves adjustments to the financial statements at the beginning of the year
□Applicable √N/A
Hereby the announcement is made.
Joincare Pharmaceutical Group Industry Co., Ltd.
25 April, 2024